Evidence map›Paper›PMID 28815614›Full record

ReviewAnnals of the New York Academy of Sciences2017

Resveratrol for Alzheimer's disease.

Christine Sawda, Charbel Moussa, R Scott Turner

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of the New York Academy of Sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 5 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 5 syntheses or guidelines pooled it, 265 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Aurantio-Obtusin Attenuates Aβ-Induced Cognitive Impairment and Synaptic Dysfunction by Suppressing Neuroinflammation in Mice.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  11. Review
  12. A dual role ofScience advances · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christine SawdaMemory Disorders Program, Department of Neurology, Georgetown University, Washington, DC.
Charbel MoussaMemory Disorders Program, Department of Neurology, Georgetown University, Washington, DC.
R Scott TurnerMemory Disorders Program, Department of Neurology, Georgetown University, Washington, DC.
Georgetown University · US

Funding

RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
NIA NIH HHS U19 AG010483
6 · The paper itself

Abstract

The amyloid hypothesis suggests that the progressive accumulation and deposition of central nervous system (CNS) amyloid with aging is the proximate cause of Alzheimer's disease (AD). Thus, targeting molecular mechanisms of aging may be a viable treatment approach. Caloric restriction prevents diseases of aging, including AD, in animal models, perhaps by activation of sirtuins. The sirtuins (e.g., mammalian SIRT1) are deacetylases that link energy balance (NAD

Indexed as

Alzheimer DiseaseBlood-Brain BarrierDouble-Blind MethodHumansResveratrolSirtuinsStilbenesTreatment OutcomeResveratrolSirtuinsStilbenesAlzheimer's diseaseamyloidpolyphenolresveratrolsirtuin

Identifiers

PMID28815614
PMCPMC5664214
OpenAlexW2747751876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.